India Pharma Outlook Team | Tuesday, 23 September 2025
Agilus Diagnostics, the flagship provider of diagnostic services in India, is a wholly-owned subsidiary of Fortis Healthcare Ltd., and has made the announcement of the introduction of its AgilusEDGE Comprehensive Genomic Profile (CGP) Rapid at its Gurugram Reference Laboratory that is state-of-the-art.
The breakthrough test facilitates comprehensive genomic profiling of more than 500 cancer-associated genes in less than four working days, thus, it not only sets a new standard but also shatters the old one in cancer diagnosis.
It was the norm that cancer genomic profiling to take such a long time as 30 days, and in most cases, the treatment of the patients could not be decided during that time. This is a next-generation sequencing (NGS) technology-powered, clinicians, and oncologists are now getting the genome they need in a fraction of the time. In other words, the treatment can be done more accurately and in a timely manner.
Dr. Anand K, Managing Director & CEO of Agilus Diagnostics, said, “As we did this in reality, the comprehensive genomic profiling turnaround time was brought more than four times lower, i.e. from nearly a month to just four working days.”
Also Read: Vidal Health, Serum Institute Partner for HPV Vaccine Access
Thus, the Agilus Diagnostics has moved a step ahead in cancer care. By virtue of being the first lab chain in India to get hold of this capability, we are not only setting new industry standards but also assuring oncologists and patients quicker access to the required insights when time is of the essence.
Agilus Diagnostics not only fulfills the promise of precision medicine that is made but goes on to create the future of cancer care in India, which is one that is more accessible and is at the forefront of the latest technological developments.
